Chemoprevention of hepatocellular carcinoma by dehydroepiandrosterone and its derivatives

脱氢表雄酮及其衍生物对肝细胞癌的化学预防

基本信息

项目摘要

Dehydroepiandrosterone (DHEA) is the most abundant adrenal androgenic steroid in young adult humans. The physiological functions of DHEA in preventing human carcinogenesis are still controversial, but a lot of reports have shown that pharmacological doses of DHEA show chemopreventive and anti-proliferative effects on tumors in rodents. The present study was undertaken to obtain basic data and methods for the clinical use of DHEA in the future. The following results were obtained.1.Sensitive and reliable method for the quantification of DHEA-related steroids by a stable isotope-dilution technique using high-resolution GC-MS was developed. The method made it possible to determine simultaneously DHEA and DHEA derivative levels in human serum. In addition, to evaluate the effects of DHEA on cholesterol metabolism, highly sensitive LC-MS/MS methods for the quantification of several key intermediates in the cholesterol and bile acid biosynthetic pathways were developed.2.The effects of DHEA … More on the proliferation of hepatic cancer cell lines were studied. We demonstrated the following four mechanisms of the anti-proliferation by DHEA : 1) depletion of NADPH and ribose-5-phosphate due to the inhibition of glucose-6-phosphate dehydrogenase activity, 2) suppression of cholesterol biosynthetic pathway by inhibition of HMG-CoA reductase activity, 3) interference with a cell proliferation signaling pathway (MAPK cascade), and 4)induction of apoptosis through the inhibition of the PI3K/Akt signaling pathway.3. Hypercholesterolemia is one of the important paraneoplastic syndromes in patients with hepatocellular carcinoma and DHEA inhibits the proliferation of hepatocellular carcinoma by inhibiting cholesterol biosynthetic pathway. Therefore, we investigated the molecular mechanisms of hypercholesterolemia associated with hepatoma by using a hepatoma-bearing rat model. As a result, hypercholesterolemia in the hepatoma-bearing rats was caused by the increased cholesterol efflux from tumors due to the activation of a nuclear receptor, LXRalpha. Over-expression of the sterol regulatory element-binding protein (SREBP) processing system contributes to the activation of LXRalpha by maintaining high tissue levels of oxysterols that are ligands for this nuclear receptor. Less
脱氢表雄酮(DHEA)是年轻人体内含量最丰富的肾上腺雄激素。DHEA在预防人类癌变中的生理作用仍存在争议,但大量报道表明,DHEA的药理剂量对啮齿动物肿瘤具有化学预防和抗增殖作用。本研究旨在为脱氢表雄酮的临床应用提供基础数据和方法。主要研究结果如下:1.建立了一种灵敏可靠的高分辨GC-MS稳定同位素稀释法测定脱氢表雄酮相关类固醇的方法。该方法可以同时测定人血清中DHEA及其衍生物的含量。此外,为了评价脱氢表雄酮对胆固醇代谢的影响,建立了高灵敏的LC-MS/MS方法来定量胆固醇和胆汁酸生物合成途径中的几个关键中间体。2.脱氢表雄酮…的作用对肝癌细胞系的增殖有较多的研究。我们论证了DHEA的四种抗增殖机制:1)通过抑制葡萄糖-6-磷酸脱氢酶的活性来耗尽NADPH和核糖-5-磷酸;2)通过抑制HMG-CoA还原酶的活性来抑制胆固醇的生物合成途径;3)干扰细胞的增殖信号通路(MAPK级联);以及4)通过抑制PI3K/Akt信号通路来诱导细胞凋亡。高胆固醇血症是肝细胞癌患者重要的副肿瘤综合征之一,DHEA通过抑制胆固醇生物合成途径抑制肝细胞癌的增殖。因此,我们利用荷瘤大鼠模型研究了高胆固醇血症与肝癌相关的分子机制。因此,携带肝癌的大鼠的高胆固醇血症是由于核受体LXRpha的激活导致肿瘤胆固醇外流增加所致。固醇调节元件结合蛋白(SREBP)处理系统的过度表达通过维持作为这种核受体配体的组织中高水平的氧固醇来促进LXRpha的激活。较少

项目成果

期刊论文数量(39)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells.
熊去氧胆酸对 HepG2 细胞中 IIA 型磷脂酶 A2 表达的抑制作用。
  • DOI:
    10.1002/hep.20630
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ikegami,Tadashi;Matsuzaki,Yasushi;Fukushima,Sugano;Shoda,Junichi;Olivier,JeanLuc;Bouscarel,Bernard;Tanaka,Naomi
  • 通讯作者:
    Tanaka,Naomi
Simultaneous determination of dehydroepiandrosterone and its 7-oxygenated metabolites in human serum by high-resolution gas chromatography-mass spectrometry
高分辨气相色谱-质谱法同时测定人血清中脱氢表雄酮及其7-氧化代谢物
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Chiba T;tokuuye K;Matsuzaki Y;et al.;Matsuzaki Y et al.;Matsuzaki Y et al.
  • 通讯作者:
    Matsuzaki Y et al.
Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone
  • DOI:
    10.1007/s00535-005-1574-3
  • 发表时间:
    2005-05-01
  • 期刊:
  • 影响因子:
    6.3
  • 作者:
    Jiang, YF;Miyazaki, T;Matsuzaki, Y
  • 通讯作者:
    Matsuzaki, Y
科学大辞典(第2版)編集委員, 医学/バイテク部門委員
科学词典(第2版)医学/生物技术部编辑委员会成员
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    伊藤進一;松崎靖司;松崎靖司
  • 通讯作者:
    松崎靖司
Miyazaki, T.et al.: "Amimo acid ratios in plasma and tissues in a rat model of liver cirrhosis before and after exercise"Hepatology Research. 27・3. 230-237 (2003)
Miyazaki, T.等:“肝硬化大鼠模型运动前后的血浆和组织中的氨基酸比率”27・3 230-237(2003)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATSUZAKI Yasushi其他文献

緩和医療の現状と今後の展望
姑息治疗的现状及未来展望
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    HIRAYAMA Aki;TOMITA Tsutomu;YOKOTA Hiroo;KASAMAKI Yuji;MATSUZAKI Yasushi;AOYAGI Kazumasa;蓮尾英明
  • 通讯作者:
    蓮尾英明

MATSUZAKI Yasushi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATSUZAKI Yasushi', 18)}}的其他基金

Invasive metabolic markers for evaluation of host factor on the pathological progress of hepatitis C patients
侵袭性代谢标志物评价宿主因素对丙型肝炎患者病理进展的影响
  • 批准号:
    23590992
  • 财政年份:
    2011
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel therapy targeting new intracellular receptors for the treatment of malignant melanoma
开发针对新细胞内受体的新疗法用于治疗恶性黑色素瘤
  • 批准号:
    21791057
  • 财政年份:
    2009
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of a novel sonodynamic therapy for skin cancers
开发一种新型皮肤癌声动力疗法
  • 批准号:
    19790769
  • 财政年份:
    2007
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells.
熊去氧胆酸对 HepG2 细胞中 IIA 型磷脂酶 A2 表达的抑制作用。
  • 批准号:
    12670457
  • 财政年份:
    2000
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Chemopreventive Role of Ursodeoxycholic Acid in Colon Cancer Model : Suppressive Effects on Enhanced Group II Phospholipase A2 Expression
熊去氧胆酸在结肠癌模型中的化学预防作用:对增强的 II 族磷脂酶 A2 表达的抑制作用
  • 批准号:
    08670555
  • 财政年份:
    1996
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of proton beam therapy for hepatocellular carcinoma
肝细胞癌质子束治疗的建立
  • 批准号:
    06670518
  • 财政年份:
    1994
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Elucidation of pathogenesis and UDCA effect mechanisms in primary biliary cirrhosis
阐明原发性胆汁性肝硬化的发病机制和UDCA作用机制
  • 批准号:
    04670407
  • 财政年份:
    1992
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似国自然基金

PDLIM3-Cholesterol-SMO轴调控SHH通路激活及其在髓母细胞瘤中的功能研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
以促内涵体逃逸聚合物PEG-P[Asp(TEP)]-cholesterol为载体构建双级脑靶向基因传递系统沉默BACE1基因的研究
  • 批准号:
    81302714
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The role of cholesterol biosynthesis in CAF for tumorigenesis
CAF 中胆固醇生物合成对肿瘤发生的作用
  • 批准号:
    23K14585
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Reducing the production of toxic Abeta peptides in Alzheimer's disease by mutating the APP cholesterol-binding site: a new therapeutic strategy?
通过突变 APP 胆固醇结合位点来减少阿尔茨海默病中有毒 Abeta 肽的产生:一种新的治疗策略?
  • 批准号:
    MR/Y013859/1
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Research Grant
A novel role of cholesterol and SR-BI in adipocyte biology
胆固醇和 SR-BI 在脂肪细胞生物学中的新作用
  • 批准号:
    10733720
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
Cholesterol-lowering drugs for treatment of pancreatitis: validation of a clinically significant novel therapeutic target and approach
用于治疗胰腺炎的降胆固醇药物:验证具有临床意义的新型治疗靶点和方法
  • 批准号:
    10585773
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
Cholesterol homeostasis in the vertebrate retina
脊椎动物视网膜中的胆固醇稳态
  • 批准号:
    10580969
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
Application of New Tools for Probing the Roles of Sphingolipids and Cholesterol in Influenza Virus Infection
应用新工具探索鞘脂和胆固醇在流感病毒感染中的作用
  • 批准号:
    10678459
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASH
NASH 中胆固醇稳态与炎症消退之间的干扰串扰
  • 批准号:
    10568478
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
Understanding of cholesterol transporter mechanisms via HS-AFM and computational modeling
通过 HS-AFM 和计算模型了解胆固醇转运机制
  • 批准号:
    22KF0153
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Healthy Heart Remnant Cholesterol Tackles Diabetes in Youth
健康的心脏残余胆固醇可治疗青少年糖尿病
  • 批准号:
    499350
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
    Salary Programs
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
以前列腺癌为模型的强化降胆固醇干预和抗肿瘤免疫
  • 批准号:
    10802975
  • 财政年份:
    2023
  • 资助金额:
    $ 6.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了